The randomized CALGB (Cancer and Leukemia Group B) trials of NACT in patients with TNBC and HER2+ tumours found that 42 and 43 per cent respectively of those initially considered to require a mastectomy were suitable for BCS after neoadjuvant therapy17,18. This evidence concerns the gene ERBB2 and cancer.